AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
🇿🇦
Sitagliptin; Metformin Hydrochloride in South Africa
6 products registered with SAHPRA — 6 active
| Brand / Product | Reg. No. | Holder | Status | Expires |
|---|---|---|---|---|
| JOSISITIN PLUS 50/500 mg | 55/21.2/0679.676 | Sandoz South Africa (Pty) Ltd | active | 28 Feb 2028 |
| JOSISITIN PLUS 50/1 000 mg | 55/21.2/0681.678 | Sandoz South Africa (Pty) Ltd | active | 28 Feb 2028 |
| GLUSITA PLUS 50/500 mg | 55/21.2/0676 | Sandoz South Africa (Pty) Ltd | active | 28 Feb 2028 |
| GLUSITA PLUS 50/850 mg | 55/21.2/0677 | Sandoz South Africa (Pty) Ltd | active | 28 Feb 2028 |
| GLUSITA PLUS 50/1 000 mg | 55/21.2/0678 | Sandoz South Africa (Pty) Ltd | active | 28 Feb 2028 |
| JOSISITIN PLUS 50/850 mg | 55/21.2/0680.677 | Sandoz South Africa (Pty) Ltd | active | 28 Feb 2028 |
Sitagliptin; Metformin Hydrochloride — SAHPRA Registration Details
SAHPRA (South Africa) has 6 registered products containing Sitagliptin; Metformin Hydrochloride, of which 6 are currently active. Data is sourced directly from the official SAHPRA drug register and refreshed daily.
Track Sitagliptin; Metformin Hydrochloride registration expiry dates, monitor competitor approvals, and receive alerts when registration status changes. Create a free account to set up portfolio monitoring.